Recent Updates
Recently added Catalysts
ALT Negative Sentiment Score: 20/100

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights – ALT

Key Takeaway: Altimmune, Inc. (NASDAQ: ALT) is facing a class action lawsuit alleging securities fraud due to misleading statements related to its lead product candidate, pemvidutide. The lawsuit claims the company overstated the drug's potential and efficacy in comparison to competing therapies. This has led to questions regarding Altimmune's market position and prospects for securing a strategic partner. Shareholders who purchased stock within the specified class period are encouraged to register for participation in the lawsuit before the July 5, 2024 deadline.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allegations of securities fraud regarding misleading statements by the company.
  • Concerns over overstated efficacy of the lead product candidate pemvidutide.
  • Potential legal repercussions and financial losses for shareholders.
  • Deadline for shareholders to register for class action set for July 5, 2024.

Full Press Release Details

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 1, 2023 to April 26, 2024
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Altimmune overstated the potential for its lead product candidate, pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
DEADLINE: July 5, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=82889&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 5, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Altimmune shareholders?

The class period for Altimmune shareholders is from December 1, 2023, to April 26, 2024.

What allegations are made against Altimmune?

The allegations include overstating the efficacy of pemvidutide and misleading investors about its potential.

What is the deadline to register for the class action?

The deadline to register for the class action is July 5, 2024.

Are there costs to participate in this case?

There is no cost or obligation to participate in the case.

How can shareholders receive updates on the case?

Registered shareholders will receive status updates via portfolio monitoring software.

Last updated: Jun 6, 2024